Discover how pharmaceutical innovation led by companies like Pfizer is transforming cancer treatment and shaping future breakthroughs.
ONCOLOGY: THE ROLE OF PHARMA IN CANCER CURE
PFIZER’S ONCOLOGY IMPACT
Pfizer continues expanding its global oncology presence, driving innovation and building therapies that address the complex needs of cancer patients worldwide.
INVESTING IN CANCER RESEARCH
With 40% of its R&D budget dedicated to oncology, Pfizer is accelerating targeted therapies and combination treatments designed for diverse cancer types.
50+ PROGRAMS IN DEVELOPMENT
Pfizer’s robust pipeline includes over 50 active cancer programs, featuring small molecules, ADCs, bispecific antibodies, and next-generation immunotherapies.
2025 ASCO BREAKTHROUGHS
Key highlights include improved survival with BRAFTOVI in colorectal cancer and strong tumor-shrinkage data for SSGJ-707 in lung cancer patients.
The FDA’s approval of BRAFTOVI marks a major step forward for patients with BRAF V600E-mutant metastatic colorectal cancer, offering a more effective targeted option.
NEXT-GEN CANCER THERAPIES
Pfizer is advancing precision-focused treatments including small molecules, ADCs, and bispecific antibodies that directly target cancer mechanisms.
PFIZER’S 2030 VISION
By 2030, Pfizer aims to double the number of patients reached with its oncology medicines through strategic research, partnerships, and improved global availability.
MOVING TOWARD A CURE
Cancer’s complexity requires collaboration. Pfizer works with leading cancer centers to develop more precise, accessible, and patient-centered therapies for the future.